Literature DB >> 22218878

Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma.

Domenico Rubello, Ka Kit Wong, Maria Cristina Marzola, Mohsen Beheshti, Valentina Ambrosini, Sotirios Chondrogiannis, Milton D Gross.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22218878     DOI： 10.1007/s00259-011-2035-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  49 in total

1.  Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Authors:  Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix M Mottaghy
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

Review 2.  Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma.

Authors:  Kim Biermann; Hans-Jürgen Biersack; Amir Sabet; Viktor Janzen
Journal:  Semin Nucl Med       Date:  2011-03       Impact factor: 4.446

3.  Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.

Authors:  Evangelia Skoura; Phivi Rondogianni; Maria Alevizaki; Marinella Tzanela; Stylianos Tsagarakis; George Piaditis; George Tolis; Ioannis E Datseris
Journal:  Nucl Med Commun       Date:  2010-06       Impact factor: 1.690

4.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

5.  Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.

Authors:  M Papotti; U Kumar; M Volante; C Pecchioni; Y C Patel
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

Review 6.  The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

Authors:  Lei Ye; Libero Santarpia; Robert F Gagel
Journal:  Endocr Rev       Date:  2010-07-06       Impact factor: 19.871

7.  Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.

Authors:  M Diehl; J H Risse; K Brandt-Mainz; M Dietlein; K H Bohuslavizki; P Matheja; H Lange; J Bredow; C Körber; F Grünwald
Journal:  Eur J Nucl Med       Date:  2001-11

8.  The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Authors:  Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

9.  PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA.

Authors:  Carine Pestourie; Benoît Thézé; Bertrand Kuhnast; Stéphane Le Helleix; Karine Gombert; Frédéric Dollé; Bertrand Tavitian; Frédéric Ducongé
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  Metabolic imaging allows early prediction of response to vandetanib.

Authors:  Martin A Walter; Matthias R Benz; Isabel J Hildebrandt; Rachel E Laing; Verena Hartung; Robert D Damoiseaux; Andreas Bockisch; Michael E Phelps; Johannes Czernin; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2011-01-13       Impact factor: 10.057
View more
  2 in total

1.  SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Authors:  Anna Margherita Maffione; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-22       Impact factor: 9.236

2.  The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine.

Authors:  Giorgio Treglia; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.